Affiliation:
1. Department of Pharmaceutics Arvind Gavali College of Pharmacy, Jaitapur, Satara, Maharashtra, India
2. Department of Pharmaceutics, Rajarambapu College of Pharmacy, Kasegaon, Maharashtra, India
Abstract
Depression is a life-threatening, debilitating, and common disease affecting different segments of community. Chemical and synthetic drugs available to treat this disease cause many adverse effects and may lead to complete recovery in only 50% of patients. Antidepressants are effective and accessible treatment options that can reduce suffering and prevent relapse of symptoms. They are recommended as first line treatment options in moderate and severe depression or mild or sub threshold depression that has persisted despite other interventions All current antidepressants, with the exception of agomelatine, increase the transmission of the monoamines, particularly serotonin, nor adrenaline and dopamine. The antidepressants are crucial for the treatment of depressive episodes in the acute phase when untreated symptoms are at their worst. With long-term use, however, the brain sets to work compensating for the drug-induced changes with a process he calls oppositional tolerance. Antidepressant drugs are the mainstay for the treatment of depression. Usually, antidepressants are given in combination with some form of limited supportive psychotherapy.
Reference37 articles.
1. Jennings, Leigh (2018). "Chapter 4: Antidepressants". In Grossberg, George T.; Kinsella, Laurence J. Clinical psychopharmacology for neurologists: a practical guide. Springer. pp. 45–71. Doi: 10.1007/978-3-319-74604-3_4. ISBN 978-3-319-74602-9.
2. World Health Organization. Mental Health. Depression. http://www.who.int/en/
3. Keller MB, Lavori PW, Rice J, et al. The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: a prospective follow-up. Am J Psychiatry 1986;143:24-8.
4. Mueller T, Leon A, Keller M, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow up. Am J Psychiatry 1999;156:1000-6.
5. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharm 2008;22:343-96.